Filtered By:
Drug: Estradiol

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 6427 results found since Jan 2013.

Individual differences in risk taking and endogeneous levels of testosterone, estradiol, and cortisol: A systematic literature search and three independent meta-analyses
Publication date: Available online 3 May 2018 Source:Neuroscience & Biobehavioral Reviews Author(s): Jennifer Kurath, Rui Mata Hormonal levels have been hypothesized to serve as proximal biological mechanisms underlying individual differences in risk taking. We conducted a systematic literature search and independent meta-analyses to assess the link between endogenous testosterone, estradiol, and cortisol levels and risk-taking related constructs (i.e., risk-taking propensity, impulsivity, sensation seeking, novelty seeking). We found small correlations between risk-taking constructs and testosterone (r = 0.12...
Source: Neuroscience and Biobehavioral Reviews - May 3, 2018 Category: Neuroscience Source Type: research

De novo transcriptome analysis to search for sex-differentiation genes in the Siberian sturgeon.
Abstract The sturgeon family includes many species that are lucrative for commercial caviar production, some of which face critical conservation problems. The purpose of this study was to identify genes involved in gonadal sex differentiation in sturgeons, contributing to our understanding of the biological cycle of this valuable species. A high-quality de novo Siberian sturgeon gonadal transcriptome was built for this study using gonadal samples from undifferentiated fish at 3, 5, and 6 months of age; recently sex-differentiated fish at 9 months of age; and immature males and females at 14-17 months of age. Undif...
Source: General and Comparative Endocrinology - August 3, 2018 Category: Endocrinology Authors: Vizziano-Cantonnet D, Lasalle A, Di Landro S, Klopp C, Genthon C Tags: Gen Comp Endocrinol Source Type: research

In search of neuroprotective therapies based on the mechanisms of estrogens.
Authors: DonCarlos LL, Azcoitia I, Garcia-Segura LM Abstract Although estradiol is a neuroprotective factor, estrogen therapy in older women increases the risk of adverse cognitive outcomes and poses additional peripheral risks, requiring careful use of estrogenic compounds as treatments for neurodegenerative conditions or neural injury. Potential alternatives to estrogen therapy to promote neuroprotection might include treatment with molecules that are able to interact with estrogen receptors, with alternative mechanisms of action, or with molecules that induce local estradiol synthesis in the brain, or a combinat...
Source: Expert Review of Endocrinology and Metabolism - February 15, 2019 Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research

Motivational increase of androgens and behavior by infant distress calls in highly responsive common marmoset fathers, Callithrix jacchus
Horm Behav. 2022 Mar 30;142:105162. doi: 10.1016/j.yhbeh.2022.105162. Online ahead of print.ABSTRACTCommon marmoset fathers are highly involved in care of their infants. However, variability exists in their response to infant behavior even in paternally experienced fathers. Using infant distress cries as a motivation test, we investigated: 1. the differences in paternally experienced fathers' motivation to search for the infant vocalization stimuli; 2. the relationship between a father's motivation to search for the source of the infant cries and testosterone levels; and 3. if there is a rapid steroidogenesis pathway leadi...
Source: Hormones and Behavior - April 2, 2022 Category: Endocrinology Authors: Natalie J Dukes Hayley Ash Gabriela de Faria Oliveira Megan E Sosa Robinson W Goy Ricki J Colman Toni E Ziegler Source Type: research

Chemopreventive and anti-tumor potential of vitamin E in preclinical breast cancer studies: A systematic review
CONCLUSION: In conclusion, vitamin E isoforms, isolated or associated, showed antitumor and chemopreventive activity. However, due to studies heterogeneity, there is a need for further analysis to establish dose, form, supplementation time and breast cancer stage.PMID:36657931 | DOI:10.1016/j.clnesp.2022.11.001
Source: Clinical Breast Cancer - January 19, 2023 Category: Cancer & Oncology Authors: Maria do Perpetuo Socorro de Sousa Coelho Irislene Costa Pereira Kynnara Gabriella Feitosa de Oliveira Iara Katryne Fonseca Oliveira M árcia Dos Santos Rizzo Victor Alves de Oliveira Felipe Cavalcanti Carneiro da Silva Francisco Leonardo Torres-Leal Jo à Source Type: research

Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception
CONCLUSIONS: There are no comparative studies assessing risk of thromboembolism in COVID-19 patients who use hormonal contraception, which was the primary objective of this review. Very little evidence exists examining the risk of increased COVID-19 disease severity for combined hormonal contraception users compared to non-users of hormonal contraception, and the evidence that does exist is of very low certainty. The odds of hospitalization for COVID-19 positive users of combined hormonal contraceptives may be slightly decreased compared with those of hormonal contraceptive non-users, but the evidence is very uncertain as ...
Source: Cochrane Database of Systematic Reviews - January 9, 2023 Category: General Medicine Authors: Megan A Cohen Alison Edelman Robin Paynter Jillian T Henderson Source Type: research

Human Health Effects of Dichloromethane: Key Findings and Scientific Issues
Conclusion: The 2011 IRIS assessment of dichloromethane provides insights into the toxicity of a commonly used solvent. Citation: Schlosser PM, Bale AS, Gibbons CF, Wilkins A, Cooper GS. 2015. Human health effects of dichloromethane: key findings and scientific issues. Environ Health Perspect 123:114–119; http://dx.doi.org/10.1289/ehp.1308030 Address correspondence to G.S. Cooper, National Center for Environmental Assessment (8601-P), U.S. Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460 USA. Telephone: (703) 347-8636. E-mail: Cooper.Glinda@epa.gov The views expressed are thos...
Source: EHP Research - February 2, 2015 Category: Environmental Health Authors: Web Admin Tags: Commentary February 2015 Source Type: research

Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids
CONCLUSIONS: Elagolix plus add-back therapy is effective in reducing menstrual bleeding associated with uterine fibroids. However, there are several warnings and precautions that must be considered.PMID:33998300 | DOI:10.1177/10600280211015987
Source: The Annals of Pharmacotherapy - May 17, 2021 Category: Drugs & Pharmacology Authors: Sarah E Lynch Danielle C Mayer Source Type: research

Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception
CONCLUSIONS: There are no comparative studies assessing risk of thromboembolism in COVID-19 patients who use hormonal contraception, which was the primary objective of this review. Very little evidence exists examining the risk of increased COVID-19 disease severity for combined hormonal contraception users compared to non-users of hormonal contraception, and the evidence that does exist is of very low certainty. The odds of hospitalization for COVID-19 positive users of combined hormonal contraceptives may be slightly decreased compared with those of hormonal contraceptive non-users, but the evidence is very uncertain as ...
Source: Cochrane Database of Systematic Reviews - January 9, 2023 Category: General Medicine Authors: Megan A Cohen Alison Edelman Robin Paynter Jillian T Henderson Source Type: research

Evaluation of Endpoints Used in Clinical Trials on Adenomyosis - A Systematic Review
Rev Recent Clin Trials. 2023 Mar 29. doi: 10.2174/1574887118666230329104546. Online ahead of print.ABSTRACTAdenomyosis lacks approved pharmacological treatment even after decades of its identification. We performed this study to review the status of clinical research on adenomyosis for finding an effective drug therapy and to identify the most common endpoints used in adenomyosis trials. A systematic search was performed in the PubMed and Clinicaltrials.gov registries to identify interventional trials for analysis without any time and language restrictions. Our search revealed that barely 15 drugs have been assessed for th...
Source: Reviews on Recent Clinical Trials - March 31, 2023 Category: Cancer & Oncology Authors: Kiran Kumar Rathinam Justin Jacob Abraham Harish K Heema Preethy S Sunita Samal Melvin George Source Type: research